Recent blog posts
Nkarta Begins Investigator-Led NKX019 Clinical Trial for Systemic Lupus Erythematosus
Latest Hotspot
3 min read
Nkarta Begins Investigator-Led NKX019 Clinical Trial for Systemic Lupus Erythematosus
31 July 2024
Nkarta Reveals Start of Clinical Trial Led by Investigators for NKX019 in Treating Systemic Lupus Erythematosus.
Read →
Initial Cancer Patient Treated with Inimmune's TLR7/8 Agonist INI-4001 in Phase 1 Trial
Latest Hotspot
3 min read
Initial Cancer Patient Treated with Inimmune's TLR7/8 Agonist INI-4001 in Phase 1 Trial
31 July 2024
Inimmune reports initial cancer patient treated in a phase 1 trial with its new TLR7/8 agonist immunotherapy, INI-4001.
Read →
Transposon's Phase 2 Results on TPN-101 for C9orf72-Linked ALS and FTD
Latest Hotspot
4 min read
Transposon's Phase 2 Results on TPN-101 for C9orf72-Linked ALS and FTD
31 July 2024
Transposon Reports Conclusive Data from Phase 2 Trial of TPN-101 Targeting C9orf72-Linked ALS and/or Frontotemporal Dementia.
Read →
Sage Therapeutics and Biogen Present Phase 2 Results of SAGE-324 (BIIB124) for Essential Tremor
Latest Hotspot
4 min read
Sage Therapeutics and Biogen Present Phase 2 Results of SAGE-324 (BIIB124) for Essential Tremor
31 July 2024
Sage Therapeutics and Biogen Reveal Key Findings from Phase 2 KINETIC 2 Trial of SAGE-324 (BIIB124) for Essential Tremor Treatment.
Read →
Pfizer Reveals Promising Phase 3 Results for Hemophilia A Gene Therapy Candidate
Latest Hotspot
3 min read
Pfizer Reveals Promising Phase 3 Results for Hemophilia A Gene Therapy Candidate
31 July 2024
Pfizer Inc. revealed encouraging topline outcomes from the Phase 3 AFFINE trial, which assesses giroctocogene fitelparvovec.
Read →
Merus Reports Initial Dosing in Phase 3 LiGeR-HN2 Trial of Petosemtamab for 2/3L r/m HNSCC
Latest Hotspot
3 min read
Merus Reports Initial Dosing in Phase 3 LiGeR-HN2 Trial of Petosemtamab for 2/3L r/m HNSCC
31 July 2024
This trial aims to assess the efficacy and safety of petosemtamab, a Biclonics targeting EGFR and LGR5.
Read →
Rhythm Pharmaceuticals Initiates Phase 2 Trial for Oral MC4R Agonist LB54640 in Hypothalamic Obesity Patients
Latest Hotspot
3 min read
Rhythm Pharmaceuticals Initiates Phase 2 Trial for Oral MC4R Agonist LB54640 in Hypothalamic Obesity Patients
30 July 2024
Rhythm Pharmaceuticals Begins Dosing First Patients in Phase 2 Trial for Oral MC4R Agonist LB54640 Targeting Hypothalamic Obesity.
Read →
Enlivex Authorized for Phase I Trial of Allocetra in Psoriatic Arthritis Patients
Latest Hotspot
3 min read
Enlivex Authorized for Phase I Trial of Allocetra in Psoriatic Arthritis Patients
30 July 2024
Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis.
Read →
Promising Phase 2 Results for OSE Immunotherapeutics' Lusvertikimab in Treating Ulcerative Colitis
Latest Hotspot
3 min read
Promising Phase 2 Results for OSE Immunotherapeutics' Lusvertikimab in Treating Ulcerative Colitis
26 July 2024
OSE Immunotherapeutics Reports Promising Phase 2 Trial Outcomes for Lusvertikimab in Ulcerative Colitis Treatment.
Read →
IASO Bio Gains U.S. FDA Green Light for Equecabtagene Autoleucel IND Application in Multiple Sclerosis
Latest Hotspot
3 min read
IASO Bio Gains U.S. FDA Green Light for Equecabtagene Autoleucel IND Application in Multiple Sclerosis
25 July 2024
IASO Biotechnology announced that the FDA has approved its application for a new drug, Equecabtagene Autoleucel (Eque-cel), a fully human anti-BCMA CAR T cell therapy.
Read →
Enterprise Therapeutics administers ETD001 to first cystic fibrosis patient in Phase 2 study
Latest Hotspot
4 min read
Enterprise Therapeutics administers ETD001 to first cystic fibrosis patient in Phase 2 study
25 July 2024
Enterprise Therapeutics has today revealed that the first participant with cystic fibrosis has been administered a dose in its Phase 2a study of ETD001.
Read →
Merck Unveils Early Results for RSV Antibody Clesrovimab in Infants
Latest Hotspot
3 min read
Merck Unveils Early Results for RSV Antibody Clesrovimab in Infants
25 July 2024
Merck Reveals Preliminary Findings from Phase 2b/3 Study of Clesrovimab (MK-1654), an Experimental Monoclonal Antibody for RSV Prevention in Infants.
Read →